Palatin Technologies
Market cap $9.5M 1.8M shares (10-Q, Nov 13, 2026) × $5.36 close Nov 17, 2026
Most recent annual filing: 2026-09-28
- Bivamelagon Rhythm Ph3 startby year-end 2026Bivamelagon Rhythm Ph3 start, by year-end 2026, routine
- Once-weekly MC4R peptide IND filing4Q 2026Once-weekly MC4R peptide IND filing, 4Q 2026, material
- Series J Warrants corporate updateMay 12, 2027Series J Warrants corporate update, May 12, 2027, notable
- Oral small molecule MC4R agonist2H 2027Oral small molecule MC4R agonist, 2H 2027, notable
- Long-acting peptide PL2000 program corporate2H 2027Long-acting peptide PL2000 program corporate, 2H 2027, notable
- Oral program IND filing2H 2027Oral program IND filing, 2H 2027, notable
- PL2001 corporate update2H 2027PL2001 corporate update, 2H 2027, notable
- Once-weekly peptide / oral MC4R2H 2027Once-weekly peptide / oral MC4R, 2H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
bremelanotide
- Erectile Dysfunction
PL9643
PL8177
PL2001
- Undisclosed indication
Technology platforms
Palatin Peptide Lipidation Technology
Proprietary lipidation platform for extending half-life of MC4R-selective peptide agonists; supports once-weekly or less frequent subcutaneous dosing; applied to PL2000-series long-acting lipidated peptide candidates targeting rare neuroendocrine obesity disorders including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome
Targets: MC4R
Discontinued (1)
- PL7737 — undisclosed · superseded: next-generation oral small molecule MC4R agonist in lead selection, 'incorporating data and program learnings from PL7737' (10-K 2026-09-28, 10-Q 2026-11-16)
Capital (as filed)
- Cash
- $3.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$3.7M quarter to Sep 30, 2026 (10-Q)
- As stated in coverage
- $3.7M cash, runway second half of calendar 2026 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-17 UPDATE: Palatin Technologies (PTN) - A Name for the Drug, Three Months of Cash 🔒 Paid
- 2026-09-29 UPDATE: Palatin Technologies (PTN) - The Clock Runs Out Before the Trigger 🔒 Paid
- 2026-09-07 Palatin Technologies (PTN) — Scientific Deep Dive for the MC4R Selective Agonist Programs and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Palatin Technologies, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-09-07 Watch Palatin Technologies (PTN) — Scientific Deep Dive for the MC4R Selective Agonist Programs and Pipeline Products No named development candidate, no human data on lead programs, and the lead indication already has an approved competitor, making this a research program rather than an investable drug asset.
- 2026-09-29 Avoid UPDATE: Palatin Technologies (PTN) - The Clock Runs Out Before the Trigger Audited going-concern language confirms runway ends in 2H 2026, Phase 1 slipped again, and the IND-forced warrant exercise now looks unlikely before the Series J hard expiry, making dilution before any data the most probable outcome.
- 2026-11-17 Avoid UPDATE: Palatin Technologies (PTN) - A Name for the Drug, Three Months of Cash Despite naming PL2001 as a development candidate with credible selectivity and PK data, cash of ~$3.7M against ~$1.5M/month burn means financing must come before any IND or human data, and the stock below warrant strikes eliminates the forced-exercise capital mechanism.
- Avoid call · opened Sep 29, 2026 at $9.12 · -41.2% vs XBI -7.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (11)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleasePalatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
- Nov 16, 2026ReleasePalatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026→ BD updateSummary on the 10-Q
- Nov 16, 202610-QQuarterly report→ BD updatePalatin finally named its development candidate — PL2001, a lipidated MC4R-selective peptide with >168-hour dog half-life and >100–200x selectivity over MC1R — but the same filing revealed cash has cratered to $3.74M, burning $3.75M in a single quarter. The science answered one question; the balance sheet raised a bigger one.
- Nov 13, 2026ReleasePalatin to Report First Quarter Fiscal Year 2027 Results
- Sep 28, 2026ReleasePalatin Reports Fiscal Year 2026 Financial Results and Provides Business Update→ BD updateSummary on the 10-KBD extracted 1 program update from this document → PTN pipeline
- Sep 28, 202610-KAnnual report→ BD updateThe FY2026 10-K confirms $7.5M cash, a going-concern warning, and another IND slip — but also names the PL1000/PL2000 peptide series for the first time, partially addressing the "unnamed candidate" problem. The Series J warrant clock is now critically short.
- Aug 3, 20268-KCurrent report: shareholder vote
- Jun 25, 2026DEF 14AProxy statement
- May 28, 202625Delisting notice
- May 18, 20268-KCurrent report: listing notice, Reg FD disclosure · EX-99.1
- May 13, 202610-QQuarterly report
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)→ BD updateSummary on the 10-Q
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- May 28, 2026CERTCERT
- May 28, 20268-A12B8-A12B
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 23, 2026SCHEDULE 13GPassive >5% holder (13G)